Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Royalty Pharma enters the final stretch before its November 6 earnings with an unusual tension: the Street has been consistently raising targets, yet the stock is sliding, trading at $56.44 after losing nearly 12% over the past month.
The most telling signal this week sits in the options market, where positioning has turned decisively bullish in structure. The put/call ratio has dropped to 0.146, more than 1.3 standard deviations below its 20-day average of 0.224, putting it close to the lowest reading of the past year. That is not the profile of a market hedging against further downside. It suggests options traders are loading calls rather than puts into the weakness, treating the selloff as an entry point rather than a warning sign. Borrow conditions reinforce the picture. Availability is extremely loose at roughly 5,600%, meaning there are far more shares available to lend than are currently shorted. Cost to borrow is running below 0.4%, down about 10% over the past month. Nothing in the lending market points to bearish pressure building.
Short interest backs that up: at 2.7% of the free float, it is low by any measure. The position grew about 7% over the past month in absolute share terms, but that accumulation appears to have stalled and even reversed this week, with shares short falling from around 11.8 million to 11.5 million over the past five days. The ORTEX short score of 35.4 sits in the lower third of the universe, consistent with a name that shorts treat as background rather than a target.
The Street has been a persistent buyer of the thesis. Morgan Stanley's Terence Flynn raised his target to $67 this morning, keeping an Overweight rating, the most recent in a long run of upward revisions from major houses. JP Morgan lifted to $62 in August after the last earnings print. TD Cowen and Citigroup both moved to the mid-to-upper $60s earlier this year. The consensus mean target is $65.38, implying roughly 16% upside from current levels. The forward earnings multiple has compressed with the share price, with the PE ratio falling by about 1.4 points over the past month to just over 10x. For a royalty model that sits in the 95th percentile for forward EPS growth momentum and scores 99th for dividend quality, that multiple is on the cheaper end of recent history.
The ownership structure adds an unusual layer of complexity. Two Schedule 13D filings are active on the register: Legorreta G. Pablo holds 18.73% of the class as last disclosed in August, down from 19.74% previously, while Butterfield Fiduciary Administrators Trust Company Limited disclosed 4.8%, down from 5.7%, in a June amendment. Both are classified as activist 13D filers, though the direction of travel on both stakes has been a slow reduction. Pablo Legorreta is the company's CEO and founder, so his 13D status reflects his founder position rather than an external activist campaign. Capital Research and Management has been adding, reaching 10.7% as of September 30 with a purchase of nearly 1.9 million shares. BlackRock similarly added 1.9 million shares in the same period. Stakes are as last disclosed around the 5% threshold, and a holder dropping below 5% may not file again.
Insider activity over the past 90 days shows net selling of around 219,000 shares worth roughly $13 million, but the context matters. Every disclosed sale in the window was executed under a pre-arranged 10b5-1 plan, including EVP Marshall Urist's regular sales in September and October and EVP Christopher Hite's larger transactions in August and September, the biggest of which totalled just under $6 million. Planned sales under 10b5-1 programs carry far less informational weight than discretionary open-market disposals.
Earnings history for RPRX shows muted reactions at the print: the August 2026 result moved the stock less than 0.4% on the day, recovering to a five-day gain of about 3%. The next print on November 6 arrives after a significant de-rating, which means the stock's response may depend less on whether royalty revenue meets estimates and more on whether management's deployment pipeline gives the market a reason to revisit the growth trajectory at a lower entry price. The divergence between a persistently bullish analyst community, loose borrow conditions, call-heavy options positioning and a stock down 12% in a month is the setup to watch into that date.
See the live data behind this article on ORTEX.
Open RPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
